• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics (NQ: CLDX )

26.47 -1.16 (-4.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Celldex Therapeutics

< Previous 1 2 Next >
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
October 26, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
October 25, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
September 25, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Inc. (NASDAQ: CLDX) Highlighted for Surprising Price Action
November 06, 2023
Via Investor Brand Network
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
September 16, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
September 12, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
July 29, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 16, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Jefferies Healthcare Conference
June 04, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
June 02, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
May 15, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 06, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
April 17, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 08, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
March 05, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 05, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
February 29, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
February 28, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 26, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
February 24, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 06, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
February 05, 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
November 27, 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
November 06, 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
November 05, 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
September 26, 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap